GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IMBdx Inc (XKRX:461030) » Definitions » Notes Receivable

IMBdx (XKRX:461030) Notes Receivable : ₩0 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is IMBdx Notes Receivable?

IMBdx's Notes Receivable for the quarter that ended in Mar. 2024 was ₩0 Mil.


IMBdx Notes Receivable Historical Data

The historical data trend for IMBdx's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMBdx Notes Receivable Chart

IMBdx Annual Data
Trend Dec21 Dec22 Dec23
Notes Receivable
- - -

IMBdx Quarterly Data
Dec21 Dec22 Mar23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial - - - - -

IMBdx Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


IMBdx Notes Receivable Related Terms

Thank you for viewing the detailed overview of IMBdx's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


IMBdx Business Description

Traded in Other Exchanges
N/A
Address
131 Gasandigital 1-ro, 21st Floor BYC Highcity Building A, Geumcheon-gu, Seoul, KOR, 08506
IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.

IMBdx Headlines

No Headlines